⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191223 | 0.78 | — | — | |
| SCHEMBL11154163 | 0.77 | — | — | |
| SCHEMBL1409155 | 0.75 | — | — | |
| SCHEMBL27858218 | 0.73 | — | — | |
| SCHEMBL27990485 | 0.73 | — | — | |
| SCHEMBL5986913 | 0.73 | — | — | |
| SCHEMBL2161000 | 0.71 | — | — | |
| SCHEMBL2121066 | 0.71 | — | — | |
| SCHEMBL22391 | 0.69 | — | — | |
| SCHEMBL1452963 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204007-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | APM THERAPEUTICS 1 INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11225490-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-01-18 | — | — | US | disclosed |
| EP-2445343-B1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-08-04 | — | — | EP | disclosed |
| US-20210196703-A1 | COMPOSITIONS OF BUPRENORPHINE AND µ ANTAGONISTS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-07-01 | — | — | US | disclosed |
| US-10954250-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-03-23 | — | — | US | disclosed |
| US-10889576-B2 | Phthalazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2021-01-12 | — | — | US | disclosed |
| US-10806731-B2 | Compositions of buprenorphine and μ antagonists | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-10-20 | — | — | US | disclosed |
| US-20200323834-A1 | HYDROPHOBIC ACID ADDITION SALTS AND PHARMACEUTICAL FORMULATIONS THEREOF | THERACAINE LLC | 2020-10-15 | — | — | US | disclosed |
| EP-3704123-A1 | HYDROPHOBIC ACID ADDITION SALTS AND PHARMACEUTICAL FORMULATIONS THEREOF | Theracaine LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10766872-B2 | Compounds for the treatment of mycobacterial infections | THE BOARD INSTITUTE, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20070259822-A1 | 8A,11-BICYCLIC 8A-AZALIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-7271155-B2 | 9A, 11-2C-bicyclic 9a-azalide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2007044927-A2 | 6, 11-BRIDGED TRICYCLIC MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| WO-2006078450-A1 | 9A, 11-2C-BICYCLIC 9A-AZALIDE DERIVATIVES | ENANTA PHARMACUETICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060154881-A1 | 9A,11-2C-bicyclic 9a-azalide derivatives | ENANTA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-7018993-B2 | Antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-03-28 | — | — | US | disclosed |
| US-20030158164-A1 | Novel antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1304334-A1 | NOVEL ANTIANDROGENIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-1219631-A1 | ANTIANDROGEN AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |